logo
Select company
Select metric
$ -192.46MEarnings Before Interest Taxes & Depreciation Amortization (EBITDA)
VS
Market
4
Sector
9
Industry
13
History
3
$ 9.84Close
$ 5.54 - $ 18.57 52-Week Range
Ticker Information

Ticker

KURA

Company Name

KURA ONCOLOGY INC

Sector

Healthcare

Industry

Biotechnology

Exchange

NASDAQ

KURA ONCOLOGY INC - Earnings Before Interest Taxes & Depreciation Amortization (EBITDA) Chart Analysis (TTM)

From
Zoom
1Y
3Y
5Y
10Y

KURA - EBITDA Historical data
DateDepreciation, Amortization & AccretionEarning Before Interest & Taxes (EBIT)Earnings Before Interest Taxes & Depreciation Amortization (EBITDA)
6/30/2025$ 877K$ -193.34M$ -192.46M
3/31/2025$ 855K$ -178.04M$ -177.19M
12/31/2024$ 848K$ -170.35M$ -169.5M
9/30/2024$ 858K$ -195.94M$ -195.08M
6/30/2024$ 866K$ -180.15M$ -179.28M
3/31/2024$ 877K$ -166.5M$ -165.63M
12/31/2023$ 849K$ -151.08M$ -150.23M
9/30/2023$ 841K$ -141.57M$ -140.73M
6/30/2023$ 818K$ -138.88M$ -138.06M
3/31/2023$ 788K$ -136.86M$ -136.07M
Previous (option currently disabled)
1 (current)
Next (option currently disabled)

Key Performance Insights, Last 5 Years

  • KURA ONCOLOGY INC's latest trailing twelve months (TTM) EBITDA stands at $ -80.67M.
  • Over the past 5 years, KURA ONCOLOGY INC's average EBITDA has been $ -140.65M.
  • The median EBITDA for KURA ONCOLOGY INC during this period was $ -135.46M
  • KURA ONCOLOGY INC reached its highest EBITDA over the past 5 years at $ -80.67M.
  • The lowest EBITDA recorded by KURA ONCOLOGY INC in the same timeframe $ -195.08M

KURA ONCOLOGY INC's EBITDA vs. competitors

We picked the following companies as peers based on multiple factors, including sector, industry, market capitalization and revenue

EBITDA Benchmarks
CompanyEBITDA
SAGE : SAGE THERAPEUTICS INC $ -300.6MNKTR : NEKTAR THERAPEUTICS $ -94.15MYMAB : Y-MABS THERAPEUTICS INC $ -26.3MTBPH : THERAVANCE BIOPHARMA INC $ 48.42MADCT : ADC THERAPEUTICS SA $ -115.26MLXRX : LEXICON PHARMACEUTICALS INC $ -107.44MZVRA : ZEVRA THERAPEUTICS INC $ 36.45MGYRE : GYRE THERAPEUTICS INC $ 9.86MGOSS : GOSSAMER BIO INC $ -128.59MTRDA : ENTRADA THERAPEUTICS INC $ -73M

Similar metrics to EBITDA:

Definition of Earnings Before Interest Taxes & Depreciation Amortization (EBITDA)

[Calculation] EBITDA is a non-GAAP accounting metric that lets investors asses profitability net of expenses dependent on financing decision, tax strategy and depreciation schedules. It is calculated by adding depreciation and amortisation expenses [DepAmor] back to [EBIT].
EBIT + DepAmor
(=) EBITDA EBITDA for KURA ONCOLOGY INC is calculated as follows: EBIT [ $ -80.75M ] + DepAmor [ $ 86K ]
(=) EBITDA [ $ -80.67M ]

KURA - Earnings Before Interest Taxes & Depreciation Amortization (EBITDA), Last 5 years

$ -195.08M

Minimum

Sep 30, 2024

$ -80.67M

Maximum

Sep 30, 2020

$ -140.65M

Average

$ -135.46M

Median

EBITDA Benchmark Analysis

 The chart above depicts the distribution of EBITDA for companies in the Total Stock Market. The average EBITDA of the companies is $ 58.79M with a standard deviation of $ 166.94M.
The following table provides additional summary stats:
EBITDA in the Market:
filtered constituents3.25K
min$ -493.3M
max$ 590.6M
average$ 58.79M
median$ 8.83M
std$ 166.94M